Ag Biologicals at a Crossroads: Four Futures, Two Uncertainties

Ag biologicals keep posting double-digit growth in some crops and regions, according to DunhamTrimmer's global biocontrol market report. Yet price competition is squeezing margins in the most commoditized categories — and that tension defines the industry's next decade, argues Gustavo Mamaao, who co-founded an agricultural biocontrol company two decades ago, sold it to Stoller 10 years later, and now advises IdeeLab, a leading Brazilian ag biological CDMO, on international partnerships.

His core problem statement is blunt: biologicals are inherently less stable than synthetic chemicals. Biological activity present at the factory door can vanish by field application if the product isn't managed properly. Fit within integrated crop and pest management systems can leave actual field performance short of promised benefits — which makes demonstrating efficacy and yield gains a significant challenge.

What's driving the market to a crossroads?

On the business side, unhealthy competition is driving down prices for commoditized products that tens — sometimes hundreds — of companies can produce. Grower purchasing decisions become relationship-based and, in most cases, driven by whoever bids lowest.

Against that backdrop, a wave of innovation platforms has made headlines: metabolites, proteins and peptides, genetically modified microorganisms, and RNAi-based solutions. These offer potential advantages in consistency, efficacy, targeted modes of action, and easier integration into established input systems. Some may also fit existing manufacturing, formulation, logistics and distribution — potentially transforming how easily biological innovation scales.

So what does this change for anyone running or investing in a company exposed to biological inputs? Mamaao frames it simply: is it time to step on the gas or the brake? The answer depends less on whether biologicals will grow, and more on which technologies will actually perform and which the existing input system can absorb.

How the scenario exercise works

Using Harvard Business School scenario-planning methodology, Mamaao set a focal issue: how might increasing commoditization and emerging innovation reshape the agricultural biological-input industry across leading markets over the next 10 years? He mapped market variables, ranked them by impact and uncertainty, and identified two high-uncertainty, high-impact driving forces:

• Ag biological technological performance — whether new platforms deliver greater product consistency.
• Corporate/channel system integration fit — how well input companies can integrate these technologies into portfolios and move them through established distribution.

The four futures

1. Biologicals at scale (strong performance + high integration fit). The technology delivers; the system is ready. Differentiated technologies take a larger role in crop-input portfolios while commoditized categories remain. Scale becomes the name of the game, favoring companies combining differentiated technology with market reach.

2. New system required (strong performance + low integration fit). The technology delivers, but the old system wasn't built for it — promising technologies hit manufacturing, distribution and application bottlenecks. Two biological markets emerge: commoditized incumbents and new value pools. "Bridge builders" — specialized manufacturers, formulation players, technology partners and new business models — win territory.

3. Integrated but incremental (incremental performance + high integration fit). Biologicals improve steadily but don't transform the game. With limited differentiation, competition shifts toward price, brand, distribution capability and bundled solutions. Portfolio players gain ground; biologicals become complements to conventional inputs.

4. Fragmented process (incremental performance + low integration fit). Technology keeps promising more than it delivers; the system stays hard to navigate and commercialization stays expensive. Commoditization meets fragmentation. Niches survive — some thrive — around particular crops, geographies and problems, but biologicals remain fragmented opportunities rather than a transformed input industry.

What does each player group face?

• Incumbents: Integration is the name of the game. If biologicals can resemble chemical molecules in stability, shelf-life and application conditions, incumbents can leverage legacy distribution and application systems. They still must invest in grower education on modes of action and integrated pest management value.
• Specialized biological companies: Challengers with over $20 million in revenue keep pushing boundaries — from fermentation players with large manufacturing capacity to dedicated distribution and sales forces. Born to challenge legacy systems, they don't need integration with them. But they must lead on innovation to avoid the commoditization trap.
• Startups: Racing to prove new platforms deliver superior performance amid scarcer capital and intense competition. They may benefit from integrating with incumbent systems — for example, peptide and protein technologies leveraging outside precision fermentation capacity for competitive pricing.

The incumbent critique

Mamaao's 20-year perspective challenges what incumbents have accomplished. Their sharing of the market with medium-sized specialized players in the $200-500 million revenue range shows, he argues, they haven't maximized their infrastructure. He's unconvinced incumbents unlocked the full potential of past acquisitions — sometimes shifting attention to other growth levers while failing to embrace biologicals' complexity. That hesitation fuels head-to-head new entrants.

He urges companies to run their own scenario simulations and track early signals: product-line commoditization metrics, startup innovation pipelines, the scale and economics of new solutions, and performance validation data. The ag inputs industry moves slowly, and results take years. In that window, each company decides whether it becomes the hunter or the prey.